Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors

Huali Wu,Jeffrey R. Infante,Vicki L. Keedy,Suzanne F. Jones,Emily Chan,Johanna C. Bendell,Wooin Lee,Beth A. Zamboni,Satoshi Ikeda,Hiroshi Kodaira,Mace L. Rothenberg,Howard A. Burris,William C. Zamboni

Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors

2013

Huali Wu
Jeffrey R. Infante
Vicki L. Keedy
Suzanne F. Jones
Emily Chan
Johanna C. Bendell
Wooin Lee
Beth A. Zamboni
Satoshi Ikeda
Hiroshi Kodaira
Mace L. Rothenberg
Howard A. Burris
William C. Zamboni

Purpose To investigate pharmacokinetics (PK) of encapsulated CPT-11, released CPT-11 and the active metabolite SN-38 following administration of IHL-305 and to identify factors that may influence IHL-305 PK.

Keywords:

Medicine
Anesthesia
Liposome
Diabetes mellitus
Population
Active metabolite
Pharmacology
Pharmacokinetics
in patient
pharmacology toxicology
population pharmacokinetics
pegylated liposomes

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations